Loss of KRASG12D feedback regulation involving splicing factor SRSF1 accelerates pancreatic cancer
L. Wan, K.-T. Lin, M. A. Rahman, Z. Wang, M. A. Jensen, Y. Park, D. A. Tuveson, A. R. Krainer
Abstract
The gene encoding KRAS GTPase is recurrently mutated in pancreatic ductal adenocarcinoma (PDAC), triggering the formation of precursor lesions, i.e., acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN). However, the majority of pancreatic cells from KC (LSL-KrasG12D/+; Pdx-1-Cre) mice expressing the KrasG12D mutation remain morphologically normal for a long time, suggesting the existence of compensatory feedback mechanisms that buffer aberrant KrasG12D signaling, and that additional steps are required for disrupting cell homeostasis and promoting transformation. Here we report a feedback mechanism in which the ubiquitously expressed splicing factor SRSF1--which is associated with cell transformation in multiple cell types--is downregulated in the majority of morphologically normal pancreas cells with the KrasG12D mutation. Conversely, increasing SRSF1 expression disrupts cell homeostasis by activating MAPK signaling, in part by regulating alternative splicing and mRNA stability of interleukin 1 receptor type 1 (Il1r1). This disruption in homeostasis in turn accelerates KrasG12D-mediated PDAC initiation and progression. Our results demonstrate the involvement of SRSF1 in the pancreatic-cell homeostatic response against the KrasG12D mutation, dysregulation of which facilitates PDAC initiation. One-Sentence SummarySplicing factor SRSF1 is involved in KRASG12D feedback regulation and pancreatic-cancer tumorigenesis.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancer
D. K. Cheng, T. E. Oni, … D. A. Tuveson·bioRxiv·Sep 14, 2020
- KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development
S. L. Tinsley, R. A. Shelley, … B. Allen-Petersen·bioRxiv·Jul 1, 2023
- Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis
Adrien Grimont, David J. Falvo, … Rohit Chandwani·Developmental CellPeer-reviewed·Jul 21, 2026
- MYC-Driven Activation of USP39 Enhances SRSF1 Stability and Promotes PDAC Progression
Benteng Ma, Xin Zhang, … Ledong Wan·Molecular Cancer ResearchPeer-reviewed·Jun 11, 2026
- Ductal pancreatic cancer interception by FGFR2 abrogation
Claudia Tonelli, Astrid Deschênes, … David Arthur Tuveson·Cancer ResearchPeer-reviewed·Apr 2, 2025
- Oncogenic KRAS cells use Wnt signalling and cell dormancy to override homeostatic cell elimination mechanisms in adult pancreas.
Beatriz Salvador-Barberó, Markella Alatsatianos, … Catherine Hogan·GastroenterologyPeer-reviewed·Apr 8, 2025